These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 11883694)

  • 1. DNA gene fusion vaccines against cancer.
    Zhu D; Stevenson FK
    Curr Opin Mol Ther; 2002 Feb; 4(1):41-8. PubMed ID: 11883694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
    Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
    Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N; King CA; Vitetta ES; Stevenson FK
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines: precision tools for activating effective immunity against cancer.
    Rice J; Ottensmeier CH; Stevenson FK
    Nat Rev Cancer; 2008 Feb; 8(2):108-20. PubMed ID: 18219306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of priming cytotoxic T cell response and strategy for enhancing DNA vaccine potency in DNA immunization].
    Deng X; Cai M
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Mar; 20(1):175-9. PubMed ID: 12744193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA tumor vaccines.
    Wlazlo AP; Ertl HC
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):1-11. PubMed ID: 11266084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
    Dobaño C; Rogers WO; Gowda K; Doolan DL
    Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo.
    Ye J; Chen GS; Song HP; Li ZS; Huang YY; Qu P; Sun YJ; Zhang XM; Sui YF
    Cancer Immunol Immunother; 2004 Sep; 53(9):825-34. PubMed ID: 15127237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
    Fredriksen AB; Sandlie I; Bogen B
    Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin.
    Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccines to attack cancer.
    Stevenson FK; Ottensmeier CH; Johnson P; Zhu D; Buchan SL; McCann KJ; Roddick JS; King AT; McNicholl F; Savelyeva N; Rice J
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14646-52. PubMed ID: 15292504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune therapy against tumors based on the ubiquitin-proteasome pathway].
    Himeno K; Hisaeda H
    Fukuoka Igaku Zasshi; 2007 Aug; 98(8):312-9. PubMed ID: 17907447
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytokine gene-engineered vaccines.
    Forni G; Boggio K
    Curr Opin Mol Ther; 1999 Feb; 1(1):34-8. PubMed ID: 11249681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccination against tumors.
    Prud'homme GJ
    J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.